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Abstract
Background: Recessive mutations of fibroblast growth factor 3 (FGF3) can cause LAMM syndrome (OMIM 610706),
characterized by fully penetrant complete labyrinthine aplasia, microtia and microdontia.
Methods: We performed a prospective molecular genetic and clinical study of families segregating hearing loss
linked to FGF3 mutations. Ten affected individuals from three large Pakistani families segregating FGF3 mutations
were imaged with CT, MRI, or both to detect inner ear abnormalities. We also modeled the three dimensional
structure of FGF3 to better understand the structural consequences of the three missense mutations.
Results: Two families segregated reported mutations (p.R104X and p.R95W) and one family segregated a novel
mutation (p.R132GfsX26) of FGF3. All individuals homozygous for p.R104X or p.R132GfsX26 had fully penetrant
features of LAMM syndrome. However, recessive p.R95W mutations were associated with nearly normal looking
auricles and variable inner ear structural phenotypes, similar to that reported for a Somali family also segregating
p.R95W. This suggests that the mild phenotype is not entirely due to genetic background. Molecular modeling
result suggests a less drastic effect of p.R95W on FGF3 function compared with known missense mutations
detected in fully penetrant LAMM syndrome. Since we detected significant intrafamilial variability of the inner ear
structural phenotype in the family segregating p.R95W, we also sequenced FGF10 as a likely candidate for a
modifier. However, we did not find any sequence variation, pointing out that a larger sample size will be needed
to map and identify a modifier. We also observed a mild to moderate bilateral conductive hearing loss in three
carriers of p.R95W, suggesting either a semi-dominant effect of this mutant allele of FGF3, otitis media, or a
consequence of genetic background in these three family members.
Conclusions: We noted a less prominent dental and external ear phenotype in association with the homozygous
p.R95W. Therefore, we conclude that the manifestations of recessive FGF3 mutations range from fully penetrant
LAMM syndrome to deafness with residual inner ear structures and, by extension, with minimal syndromic features,
an observation with implications for cochlear implantation candidacy.
Background
Sensorineural hearing loss is one of the most common
congenital disorders, affecting at least 1 in 1,000 births
[1,2]. Up to 39% of sensorineural deafness is associated
with radiologically detectable inner ear malformations
[3-5]. Among those anomalies, complete labyrinthine
aplasia (CLA), also known as “Michel aplasia,” is reported
to comprise 1% of cochlear bony abnormalites [6].
CLA merits special consideration since it precludes
cochlear implantation due to the lack of a spiral ganglion
and cochleovestibular nerve fibers [7-10]. CLA has been
reported in association with other anomalies [11,12]
including thalidomide embryopathy [11], microtia and
microdontia [13]. Until recently, the etiology of CLA was
unknown except for cases associated with thalidomide
exposure [11].
Mendelian inheritance was initially suggested for some
cases of CLA, but no genetic linkage data were reported
[14,15]. Tekin and co-authors subsequently described an
autosomal recessive deafness phenotype, now referred to
as LAMM syndrome (OMIM 610706), comprising CLA,
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regated with recessive mutations of the gene encoding
fibroblast growth factor 3 (FGF3; OMIM 164950) on
chromosome 11q13.2-q13.3 [9,10]. A total of five
Turkish families and one Saudi family segregating
LAMM syndrome and recessive FGF3 mutations have
been reported to date [7,9,10]. All of the affected indivi-
duals had fully penetrant LAMM syndrome with CLA,
microdontia, and type I microtia in which the auricle
has a dysmorphic helix and antihelix but different parts
of the auricle are still recognizable. In addition, temporal
bone CT images of 14 affected members of the pre-
viously reported families revealed complete labyrinthine
aplasia, although a cystic vestibulum was detected once
[7,9,10]. Ramsebner et al. (2009) recently reported a
missense FGF3 mutation (p.R95W) associated with less
severe phenotypes, clinically distinct from those of
LAMM syndrome [16]. However, it was not clear
whether this mild phenotype in the Somali family is due
to the mutation, genetic background or both.
Mice deficient for FGF3 do not model LAMM syn-
drome but rather have abnormal inner ears with variable
penetrance and expressivity on a uniform genetic back-
ground [17-19]. In mice, Fgf3 is expressed in the otic
vesicle and in the adjacent hindbrain during otic placode
induction and subsequent early inner ear morphogenesis
[18,20]. Loss-of-function data from mice suggest that
FGF3 affects molecular patterning of the dorsal otocyst
and dorsal otic gene expression that is induced by WNT
signals, but it does not critically influence ventrally
expressed otic genes important for cochlear develop-
ment [18].
Here we report three Pakistani families co-segregating
profound recessive deafness with mutant alleles of
FGF3. In one family, a recessive p.R95W mutation was
associated with a variable inner ear and auricular pheno-
type, similar to the reported mild phenotype of this
allele [16]. Unlike in the Somali family, significantly
milder dental phenotypes were also observed in this
Pakistani family. Therefore, we conclude that the pheno-
typic spectrum of recessive FGF3 mutations range from
fully penetrant LAMM syndrome to deafness with resi-
dual inner ear structures and absent or minimal syndro-
mic features. We also suggest that p.R95W might exert
a semi-dominant effect upon the function of FGF3.
Methods
Subject enrollment
This study was approved by the Institutional Review
Board (IRB) at the National Centre of Excellence in
Molecular Biology (NCEMB), Lahore, Pakistan
(FWA00001758) and the Combined Neuroscience IRB
at the National Institutes of Health, USA (OH-93-N-
016). Written informed consent was obtained from
adult subjects and parents of minor subjects. We ascer-
tained five Pakistani families (PKDF537, PKDF702,
PKDF295, PKDF817 and PKDF887) segregating pro-
found hearing loss significantly linked to a 4.81-cM
interval on human chromosome (11q13.2-q13.3), which
was designated as the DFNB63 locus [21]. Four families
were previously reported [21] and one family (PKDF887)
was identified through a subsequent screen with micro-
satellite markers (D11S4113, D11S4136 and D11S4162)
linked to this locus. We obtained clinical data only on
the auditory phenotype when these families were initi-
ally ascertained. Genomic DNA from affected members
of the five families was extracted from 10 ml of periph-
eral venous blood as described [22]. FGF3 is linked to
LRTOMT, in which recessive mutations are associated
with non-syndromic deafness DFNB63 [23,24]. Among
our five study families segregating deafness linked to
chromosome 11q13.2-q13.3, one family (PKDF702) was
shown to have recessive mutations in LRTOMT [23].
Mutation screening of FGF3 and 10
Primers for polymerase chain reaction (PCR) amplification
and FGF3 and FGF10 sequencing were designed using Pri-
mer3 (http://frodo.wi.mit.edu/primer3/). Methods for
direct sequencing of PCR products were described pre-
viously [22]. BigDye terminator reaction products were
resolved on an ABI3730 instrument. Sequencing traces
were analyzed with the SeqMan Pro tool of DNASTAR
Lasergene software (http://www.dnastar.com). FGF10 was
screened since it was considered to be a candidate modi-
fier of FGF3.
Molecular modeling
To better understand the structural consequences of
p.R95W that we detected in this study, we modeled the
three-dimensional structure of FGF3 using the SWISS-
MODEL server [25] and FGF10, an orthologue with the
greatest sequence identity and with available crystallo-
graphic coordinates as a template. This model was then
docked on FGFR2b in a manner similar to that seen in
the FGF10-FGFR2b complex (1NUN.PDB) [26].
Phenotype analysis
After the detection of mutations of FGF3, affected and
unaffected family members were clinically re-evaluated.
Hearing was evaluated by pure tone audiometry at
octave frequencies with intensities up to 100 dB HL.
Facial nerve and vestibular function was evaluated by
facial expressions and tandem gait/Romberg testing,
respectively. We applied the staging system of microtia
described by Weerda et al. [27]. Computed tomography
(CT) and magnetic resonance imaging (MRI) of the
temporal bones were performed, when possible, to
examine middle and inner ear structures, and the
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viduals. The MR images were acquired with a 1.5-T sys-
tem and a T2-weighted fast spin-echo sequence
(repetition time, 3920 ms; echo time, 94 ms; slice thick-
ness, 3 mm) and/or 3D fast imaging with steady state
acquisition (3D FIESTA) (repetition time, 7 ms; echo
time, 3 ms, slice thickness, 0.8 mm).
Results
FGF3 mutations in DFNB63-linked families
We identified homozygous FGF3 mutations co-segregat-
ing with deafness in three families (PKDF295, PKDF817
and PKDF887). Families PKDF537 and PKDF702
did not segregate FGF3 mutations. One mutation
(p.R132GfsX26 (c.394delC) from family PKDF887) was
novel and the other two mutations (p.R95W (c.283 C >
T) from PKDF817 and p.R104X (c.310C > T) from
PKDF295) were previously reported (Table 1; Figure 1)
[9,16]. These mutations were not found in 162 ethnically
matched Pakistani normal-hearing control individuals,
indicating that the variants are not common polymorph-
isms. The p.R132GfsX26 mutation is predicted to pro-
duce a frameshift at codon 132 followed by 25 missense
amino acids and premature termination, resulting in the
truncation of one third of the FGF3 protein. The p.
R95W associated with the milder phenotype affects a
residue that is highly conserved in known FGF3 ortho-
logs (Figure 1). Since we detected significant intrafami-
lial variability of the inner ear structural phenotype in
the family segregating p.R95W (see below), we also
sequenced FGF10 as a likely candidate for a modifier
b u tc o u l dn o tf i n da n ym u t a t i o ni nFGF10 from family
PKDF817.
The affected homozygotes are profoundly deaf (data
not shown). Interestingly, in contrast to heterozygous
carriers from PKDF295 and PKDF887, all of the three
tested heterozygous carriers of p.R95W in family
PKDF817 (PKDF817 IV-5, V-6 and V-9) showed a mild
to moderate degree of bilateral conductive hearing loss
(Figure 1D), while having a normal auricular and dental
phenotype (data not shown). However, we cannot rule
out otitis media in these carriers due to a lack of tympa-
nometric data. The variant (c.283C > T) associated with
the variable phenotype has no predicted effect upon
splicing using ESEfinder v3.0 (http://rulai.cshl.edu/cgi-
bin/tools/ESE3/esefinder.cgi?process = home) or BDGP
(http://www.fruitfly.org/seq_tools/splice.html) programs.
Therefore, it is unlikely that this variant creates a cryptic
splice site or perturbs an exonic splice enhancer site
that would lead to a leaky splice mutation.
Auricular and dental phenotype
The clinical findings for our subjects, Somali subjects
homozygous for p.R95W, and the previously reported
LAMM subjects [7,9,10,16] are summarized in Table 1.
Whereas all of the affected individuals with homozygous
FGF3 mutations from our three study families are pro-
foundly deaf, they had variable auricular and dental
anomalies (Table 1). We did not observe facial nerve
dysfunction in any of the affected subjects.
There was incomplete formation of the superior helix
and helical crus of affected members of families
PKDF295 and PKDF887. This resulted in shortened
auricles with indiscernible cymba conchae, compatible
with type I microtia (Figure 2A-B). We detected no
distinct abnormal auricular findings in most of the
affected p.R95W homozygotes from family PKDF817
(Figure 2C). Affected members of families PKDF295 and
PKDF887 showed microdontia with conical, sharp
and pointed lateral incisors( w h i t ea r r o w ,F i g u r e2 )
and widely spaced teeth. In contrast, many of the
affected members of PKDF817 had a subtle dental phe-
notype (Figure 2C). PKDF817 V-3, V-4 and V-5 indivi-
duals did not show wider interdental distances
compared with those from a heterozygous carrier of the
missense mutation. Individuals V-8 and V-10 from
family PKDF817 showed neither malformed lateral inci-
sors nor unusually wide inderdental spaces (Figure 2C).
Inner ear phenotype
We obtained temporal bone CT scans, T2-weighted/3D
FIESTA MR images, or both from ten affected indivi-
duals (two from family PKDF295, two from PKDF887
and six from PKDF817) and three heterozygous indivi-
duals (one from each family). Heterozygous carriers of
p.R104X (III-3, PKDF295), p.R132GfsX26 (III-1,
PKDF887) and p.R95W (V-2, PKDF817) did not show
any abnormal findings. The images demonstrated bilat-
eral CLA in all four deaf members of PKDF295 and
PKDF887 and in four of the six deaf members of
PKDF817 (Table 1 and Figure 3). These subjects lacked
all inner ear structures, including cochlear, vestibule,
and all semicircular canals (white arrows, Figure 3B-C
and 3E-G). The internal auditory canal (IAC) was also
aplastic and the cochleovestibular nerve was not
detected by T2-weighted MRI (Figure 3 panels I, L are
from PKDF295 IV-2 while panels J, M are from
PKDF887 IV-3). All affected individuals show normal
middle ear development. However, the degree of mas-
toid and middle ear pneumatization was variable among
affected individuals.
Partial development of the labyrinth was observed in
two p.R95W homozygotes, including one (PKDF817
V-3) with a cochlear basal turn, vestibule, and posterior
semicircular canal (Figure 3D and 3N from PKDF817
subject V-3), while the other four p.R95W homozygotes
had no detectable inner ear structures (Table 1). Axial
CT images showed the presence of bilateral IACs, albeit
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Family
No.
Ethnicity Subject
No.
Sex Type I
microtia
Microdontia
with conical
teeth
CT or MRI findings of inner ear Nucleotide
change
b
Effect
b Reference
PKDF 817 Pakistani V:1 M Normal + Bi-CLA c.283C > T p.R95W [16]
V:3 M Normal + Rt-dysplastic SCC, bony IAC(+), single
cochleovestibular nerve Lt-One and a half
turn of cochlea, short broad cystic LSC
confluent with the vestibule, bony IAC(+)
V:4 F Normal + Bi-CLA
V:5 F Normal + Not available
V:7 M Normal + Rt-Reminiscent of cochlear basal turn, Lt-CLA
V:8 M Normal Equivocal Bi-CLA
V:10 F Normal Equivocal Bi-CLA
PKDF 295 Pakistani IV:1 F + + Bi-CLA Bi- Subarachnoid cyst c.310C > T p.R104X [9]
IV:2 M + + Bi-CLA Bi- Subarachnoid cyst
IV:7 M +
a +
a Not available
IV:8 M +
a +
a Not available
PKDF 887 Pakistani IV:2 M + + Bi-CLA Bi-Subarachnoidal cyst c.394delC p.R132GfsX26 this study
IV:3 M + + Bi-CLA Bi- Subarachnoid cyst
IV:4 F +
a +
a Not available
Somali
family
Somali 3 F + + Rt- One and a half turn of cochlea, Lt-CLA c.283C > T* p.R95W [16]
5 M + + Bi-CLA
7 F Normal + Rt-CLA Lt-Common cavity
8 F + + Bi-CLA
1 Turkish 1 F + + Bi-CLA c.255delT p.I85MfsX15 [10]
2 Turkish IV:1 F + + Lt-CLA, Rt-Rudimentary cystic vestibule, but
no bony IAC Bi-Subarachnoid cyst
c.17T > C p.L6P [10]
IV:2 M + + Bi-CLA
IV:3 M + + Bi-CLA
3 Turkish 1 M + + Bi-CLA c.466T > C p.S156P [9]
2 M + + Bi-CLA
3 M + + Bi-CLA
4 M + + Bi-CLA
5 F + + Bi-CLA
4 Turkish 1 M + + Bi-CLA c.310C > T p.R104X [9]
2 M + + Bi-CLA
3 M + + Bi-CLA
5 Turkish 1 F + + Bi-CLA c.616delG p.V206SfsX13 [9]
1 Saudi VI:8 F + + Rt-CLA, Lt-rudimentary cystic vestibule, but
no bony IAC
c.196G > T p.G66C [7]
VI:9 M + + Not available
IV:3 M + + Bi-CLA Bi- Subarachnoid cyst
IV:4 F +
a +
a Not available
aInferred from observations by family members.
bMutations numbered according to NM005247.2 (cDNA) and NP_005238 (protein).
*Ramsebner et al. (2009) reported this allele as c.284C > T, but the wild type nucleotide at 284 is a G.
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Page 4 of 11Figure 1 Pedigrees, mutations and clinical data. (A) Pedigrees of Pakistani families segregating prelingual hearing loss and mutations of FGF3.
The maximum LOD scores for these families are 4.26 [21], 2.5 [21] and 4.87, respectively. Individuals with less severe phenotypes are shown with
grey shading. (B) Wild type and mutant alleles of FGF3 from unaffected and affected members of families PKDF295, PKDF887 and PKDF817.
(C) ClustalW alignment of FGF3 amino acid residues 86-109 shows that Arginine residue at position 95 (p.R95, arrow) is conserved in a variety of
species. The mutated amino acid residue in human FGF3 was numbered according to NM_005247.2 (cDNA) and NP_005238 (protein). (D) Pure
tone audiometry results for three heterozygous carriers of p.R95W who show a mild to moderate degree of conductive hearing loss with air-
bone conduction threshold gaps that range from 20 to 35 dB.
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(Figure 3N). The facial nerve and a single cochleovestibu-
lar nerve bundle were observed on the right side (arrow,
Figure 3O), but only the facial nerve was detected in the
left temporal bone in axial 3D-FIESTA MR images.
Another affected member of this family (V-7) also had a
rudimentary cochlear basal turn on the right side
(Table 1). A probable subarachnoid cyst was detected in
all four affected members of PKDF295 and PKDF887
with MR images available for review (Figure 3I-J), as pre-
viously described for another LAMM subject [10].
Molecular modeling
The common core of all FGFs consists of 140 amino
acids that fold into a ß-trefoil domain. One surface of
this domain is typically involved in heparan sulfate
Figure 2 Auricular and dental findings of affected members of families with recessive FGF3 mutations. (A) Type I microtia with
shortening of the superior portions of the auricles, overfolded helices and anteverted pinnae are shown as well as microdontia with conical,
sharp and pointed lateral incisors (white arrows) in PKDF295 IV-1 and IV-2. (B) Type I microtia with shortening of the superior portions of the
auricle caused by incomplete formation of the upper helix and helical crus. The antihelix and antihelical crura (black arrow) are relatively well
developed. (C) Normal auricles of deaf individuals from family PKDF817. Some individuals, especially V-8 and V-10, show a milder dental
phenotype compared with those in families PKDF295 and PKDF887.
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Page 6 of 11Figure 3 Radiological images from affected individuals with FGF3 homozygous mutations. Images (A through G) are axial temporal bone
CT sections. (A) Inner ear structures (Internal auditory canal (IAC), cochlea, and vestibule) in petrous bone are clearly seen (white ellipsoid) in a
normal subject. (B, C, E, F, and G) Complete labyrinthine aplasia with a flat medial wall (white arrows) of the middle ear cavity. (D) A narrow IAC
(black arrowhead), posterior semicircular canal and vestibule (white asterisk) are visible. Images (H-J and K-M) are coronal and axial sections,
respectively, of T2-weighted MR images (T2WI) of the cerebellopontine angle region. Affected individuals, PKDF295 IV-2 (I and L) and PKDF887
IV-3 (J and M) have a presumed subarachnoid cyst (black asterisk). The cochleovestibular nerve and inner ear structures (white arrow) detected in
a normal subject (H and K) are not clearly seen in affected subjects (I, J and M). Images (N and O) are contiguous axial temporal bone CT
sections and axial 3D-FIESTA MR images from PKDF817 V-3, respectively. (N) The osseous IAC (white arrowhead), vestibule (white asterisk), and
1-1/2 turns of the cochlea (black arrow) can be identified in the left ear. The vestibule and posterior semicircular canal are shown in the right
ear. (O) The presence of a single cochleovestibular nerve (white dotted arrow) can be identified in the right side. Cochlea, vestibule and
posterior semicircular canal are shown in the left ear.
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binding. We mapped p.R95W, associated with a milder
phenotype, onto the model of FGF3. Two other mis-
sense mutations (p.G66C [7] and p.S156P [9]) that were
associated with fully penetrant LAMM syndrome were
also mapped for comparison (Figure 4). Arginine (R) at
residue 95 (Arg 95) is located away from both the
FGFR2b receptor and heparan sulfate binding sites of
the FGFs (Figure 4). While an arginine to tryptophan
mutation is non-conservative, both side-chains have a
hydrophobic section and the capacity to form hydrogen
bonds. Given the partially buried nature of the R95 side
chain, replacement of this residue with the more bulky
tryptophan (W) could be accommodated with some
degree of protein destabilization, but not a complete
loss of activity. In contrast, the p.G66C mutation
detected in subjects with fully penetrant LAMM syn-
drome introduces a partially buried cysteine (Cys) resi-
due in FGF3. As a half cysteine, the reactivity of this
thiol group is likely to lead to a reduced functional half-
life for FGF3 (p.G66C), as has been well documented in
analyses of other FGFs [28,29]. The other possibility is
the formation of a disulfide bond, but the nearest
cysteine at position 50 is too far to allow disulfide link-
age without conformational changes. Interestingly a
cysteine residue in FGF15/19 at the position structurally
similar to Cys 66 in FGF3 forms a disulfide bond with a
Cys 12 to its N-terminus [30]. While a similarly posi-
tioned cysteine is not present in FGF3, it is conceivable
that an altered conformation could allow Cys 50 to be
disulfide linked with Cys 66 of FGF3. With regard to
p.S156P that was also detected in LAMM syndrome
patients, serine at residue 156 (Ser 156) is located near
the putative basic heparin binding site of the FGFs
referred to as the glycine-box [31]. Structural studies
have shown that FGF interaction with heparin can
accommodate a large degree of sequence variation in
the FGFs since much of the interaction involves van der
walls contact with the protein backbone between the
e q u i v a l e n to fr e s i d u e s1 5 8a n d1 7 4o fF G F 3[ 3 2 ] .I ti s
possible that p.S156P alters the peptide backbone in this
region enough to affect binding of heparan sulfate and
thus alter the stability of the FGF signalling complex.
Discussion
Recessive FGF3 mutations associate with a broad spec-
trum of inner ear and craniofacial phenotypes that show
inter- and intrafamilial variability. Our study confirms
that at least some recessive mutations of FGF3 may not
always result in fully penetrant LAMM syndrome.
Furthermore, we noted a less prominent dental pheno-
type in subjects with p.R95W,i nc o n t r a s tt ot h es e v e r e
dental phenotype reported from the Somali family [16].
Taken together, our results show that the manifestations
of recessive FGF3 mutations can involve nearly non-syn-
dromic deafness with variable inner ear structural devel-
opment. In this regard, mutations of either LRTOMT
[23] or FGF3 should be considered when incompletely
characterized nonsyndromic deafness is found to be
linked to genetic markers of the DFNB63 locus on chro-
mosome 11q 13.2 -q13.3.
The less severe phenotype associated with p.R95W
segregating in Pakistani family PKDF817 is probably not
due solely to genetic background, since the milder phe-
notype of homozygous p.R95W individuals has also
been reported in an unrelated family from Somalia. The
amino acid substitution of p.R95W may have a milder
pathogenic effect as compared with other mutations of
FGF. Our molecular modeling results support the possi-
bility of less severe pathogenic effects of this allele since
this variant is predicted to affect neither FGFR2b recep-
tor nor heparan sulfate binding sites. Alone or in combi-
nation with a less severe pathogenic potential of
p.R95W, there might be a differential effect of mutant
alleles of FGF3 on different target organs. While these
molecular models provide a plausible rationale for the
effects of the mutations identified here, there remains
the caveat that available structural information does not
account for the role that receptor glycosylation might
play in FGF interaction. In addition, phenotypic variabil-
ity within and between the affected individuals in these
two families also indicates a role for environment, sto-
chastic events, genetic background, or a combination of
these influences. In affected members of family
PKDF817, we could not find a variant in FGF10,a
potential candidate for a modifier of FGF3. To address
the presence of modifiers, if any, larger families segre-
gating a milder phenotype and p.R95W would be
required for linkage analyses.
Our identification of a mild to moderate conductive
hearing loss in heterozygous carriers raises the question
of whether p.R95W exerts a semi-dominant pathogenic
effect upon the function of FGF3. These data warrant
c a r e f u li n t e r p r e t a t i o n ,s i n c ew ew e r eu n a b l et oo b t a i n
information about the status of the tympanic membrane
and ossicles in carriers. We initially reasoned that this
may reflect the same pathogenic mechanism underlying
autosomal dominant lacrimo-auriculo-dento-digital syn-
drome (LADD syndrome; OMIM 149730) caused by
heterozygous mutations of FGFR2b [33]. FGF3 is known
to bind to FGFR2b with high affinity [34,35]. Some
patients with LADD syndrome have been reported to
show isolated mild conductive hearing loss [36],
although many patients manifest a mild to moderate
mixed type hearing loss. Moreover, the dental and auri-
cular phenotypes from LADD syndrome patients are
very similar with those in LAMM syndrome, while
another autosomal dominant oto-dental syndrome
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Page 8 of 11Figure 4 A homology model of FGF3 generated using the structure of FGF10 (1NUN.PDB) as a template and the SWISS-MODEL server.
FGF3 was then docked on the structure of FGFR2b in a manner identical to that of FGF10 in the FGF10-FGFR2b complex. FGFR2b is represented
by the tan cartoon, while FGF3 is shown as a ribbon color coded from the N- to the C-terminus in blue to red. The residues Gly 66, Arg 95 and
Ser 156 are shown as spheres. The image was generated using PYMOL [25].
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Page 9 of 11(MIM 166750) recently reported in association with
heterozygous microdeletions affecting FGF3 [37] shows
significantly different dental phenotypes. In this regard,
this possible semi-dominant phenotype might be consis-
tent with the hypothesis that p.R95W affects the interac-
tion between FGF3 and FGFR2 [16]. However, our
molecular modeling results argue against this hypoth-
esis, since p.R95 is located away from the FGFR2b bind-
ing surfaces of FGF3. Alternatively, an allele of a totally
different gene accounts for the hearing loss in p.R95W
heterozygous carriers in the inbred family PKDF817, as
the Somali p.R95W heterozygotes were reported not to
have hearing loss [16] The resolution of this question
will require careful molecular and clinical examination
of additional carriers of this allele and other mutations
of FGF3. The inner ear phenotypic variability within
families is consistent with t h eh i g h l yv a r i a b l ei n n e re a r
phenotype of Fgf3 knockout mice on a uniform genetic
background [18,19] and functional redundancy of Fgf3
and Fgf10 in otic vesicle formation [17,38].
The options for auditory rehabilitation of LAMM
patients with CLA are limited to vibrotactile hearing
devices or brainstem implants. The presence of an oss-
eous IAC and a cochleovestibular nerve has never been
described in association with homozygous FGF3 muta-
tions before this study. The presence of a cochleovestib-
ular nerve and a cochlear remnant is a significant
consideration for cochlear implantation candidacy.
Because of intrafamilial variability, some patients with
FGF3-related hearing loss are potential candidates for
cochlear implantation, even if CLA has already been
documented in other affected family members.
Conclusions
We conclude that the manifestations of recessive FGF3
mutations range from fully penetrant LAMM syndrome
to deafness with residual inner ear structures and, by
extension, with minimal syndromic features.
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